Genetic polymorphisms located in TGFB1, AGTR1, and VEGFA genes are associated to chronic renal allograft dysfunction

BackgroundPersistent inflammation and fibrosis have been related to active progression of renal deterioration and reduced survival of kidney transplant. The aim of this study was to determine the impact of single-nucleotide polymorphisms (SNPs) located in regions related to inflammatory and immune processes on the development of chronic renal allograft dysfunction (CRAD).MethodsA retrospective study was carried out on 276 patients who received kidney transplant (KT). SNPs were genotyped via the SNPlex platform. Statistical analysis was performed with SNPstat and regression logistic analyses were adjusted by age and gender of recipients and donors, cold ischemia time and the number of human leukocyte antigen (HLA) mismatches.ResultsFrom 276 patients with KT, 118 were non-CRAD and 158 were CRAD. Three SNPs showed significant associations with CRAD development: rs1800471 in transforming growth factor beta 1 (TGFB1), rs5186 in angiotensin II receptor type 1 (AGTR1), and rs699947 in vascular endothelial growth factor A (VEGFA). GC genotype of rs1800471 was associated with increased odds of CRAD compared to GG genotype (OR = 2.65 (95% confidence interval (CI) = 1.09; 6.47), p = 0.025), as well as AC and AA genotype of rs699947 assuming a dominant model (OR = 1.80 (95% CI = 1.02; 3.20), p = 0.044). Besides, AC and CC genotypes of rs5186 were associated with reduced odds of CRAD assuming a dominant model (OR = 0.56 (95% CI = 0.33; 0.96), p = 0.033).ConclusionOur findings suggest that three genes related to immunity and inflammation (rs1800471, rs5186 and rs699947) are associated to susceptibility or protection to CRAD, and might have diagnostic utility in predicting the likelihood of developing CRAD.

► Three SNPs located in genes related to immune and inflammatory processes were associated to CRAD.
► rs1800471, at transforming growth factor beta 1 (TGFB1) gene, showed susceptibility to CRAD.
► rs699947, at vascular endothelial growth factor A (VEGFA) gene, showed susceptibility to CRAD.
► rs5186, at angiotensin II receptor type 1 (AGTR1) gene, showed protective effect to CRAD.